

Alexander Knuth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854149/publications.pdf>

Version: 2024-02-01

167
papers

11,123
citations

43973

48
h-index

38300

95
g-index

170
all docs

170
docs citations

170
times ranked

12808
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. <i>Oncology</i> , 2021, 99, 300-309.	0.9	10
2	The effect of protein mutations on drug binding suggests ensuing personalised drug selection. <i>Scientific Reports</i> , 2021, 11, 13452.	1.6	11
3	Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.	3.3	74
4	Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus. <i>Vaccines</i> , 2020, 8, 116.	2.1	17
5	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 685-695.	0.6	1
6	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.	2.2	39
7	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41
8	β_6 -integrin serves as a novel serum tumor marker for colorectal carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 678-685.	2.3	42
9	Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. <i>BMC Cancer</i> , 2018, 18, 72.	1.1	26
10	Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1005-1012.	1.1	61
11	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	0.6	34
12	Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 18-25.	1.6	18
13	Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?. <i>Visceral Medicine</i> , 2015, 31, 434-439.	0.5	1
14	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
15	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1279-1288.	1.6	3
16	Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. <i>Immunity</i> , 2015, 42, 767-777.	6.6	135
17	Chromosomal aberrations of cancer-testis antigens in myeloma patients. <i>Hematological Oncology</i> , 2015, 33, 159-163.	0.8	1
18	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395

#	ARTICLE	IF	CITATIONS
19	Cancer testis antigen expression in testicular germ cell tumorigenesis. <i>Modern Pathology</i> , 2014, 27, 899-905.	2.9	22
20	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-CA family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. <i>International Journal of Cancer</i> , 2014, 135, 1142-1152.	2.3	46
21	Imagine a world without cancer. <i>BMC Cancer</i> , 2014, 14, 186.	1.1	12
22	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 381-394.	2.0	84
23	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 404-409.	1.6	10
24	Challenges In Adapting International Best Practices In Cancer Prevention, Care, And Research For Qatar. <i>Health Affairs</i> , 2014, 33, 1635-1640.	2.5	1
25	Innovation Can Improve And Expand Aspects Of End-Of-Life Care In Low- And Middle-Income Countries. <i>Health Affairs</i> , 2014, 33, 1612-1619.	2.5	15
26	Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. <i>Blood</i> , 2014, 124, 5570-5570.	0.6	2
27	Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. <i>Anticancer Research</i> , 2014, 34, 4693-9.	0.5	5
28	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 565-574.	1.4	13
29	Aldara activates TLR7-independent immune defence. <i>Nature Communications</i> , 2013, 4, 1560.	5.8	211
30	Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2013, 1, 288-295.	1.6	7
31	RP1 Is a Phosphorylation Target of CK2 and Is Involved in Cell Adhesion. <i>PLoS ONE</i> , 2013, 8, e67595.	1.1	7
32	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. <i>Investigative Radiology</i> , 2013, 48, 787-794.	3.5	42
33	Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature. <i>Clinical Cancer Research</i> , 2013, 19, 4843-4853.	3.2	60
34	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. <i>OncImmunology</i> , 2013, 2, e23562.	2.1	138
35	Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial. <i>Journal of Cancer</i> , 2013, 4, 597-605.	1.2	39
36	Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient. <i>Case Reports in Oncology</i> , 2013, 6, 497-503.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Abstract B1: Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation.. , 2013, , .		16
38	Abstract A18: Mouse models of autochthonous cancer to study local immune subversion.. , 2013, , .		0
39	Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Medical Weekly, 2013, 143, w13791.	0.8	3
40	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
41	NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immunity, 2013, 13, 12.	3.2	15
42	Status of hepatocellular carcinoma in Gulf region. Chinese Clinical Oncology, 2013, 2, 42.	0.4	4
43	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Oncology, 2012, 82, 333-340.	0.9	29
44	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. Oncology, 2012, 83, 1-9.	0.9	41
45	Radiotherapy supports protective tumor-specific immunity. OncoImmunology, 2012, 1, 1610-1611.	2.1	27
46	Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. Journal of Immunology, 2012, 189, 558-566.	0.4	363
47	Quantitative Perfusion Analysis of Malignant Liver Tumors. Investigative Radiology, 2012, 47, 18-24.	3.5	52
48	Automated tube potential selection for standard chest and abdominal CT in follow-up patients with testicular cancer: comparison with fixed tube potential. European Radiology, 2012, 22, 1937-1945.	2.3	49
49	Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy. Academic Radiology, 2012, 19, 613-621.	1.3	20
50	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.4	46
51	Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer, 2012, 76, 118-122.	0.9	18
52	Messenger RNA vaccination and B-cell responses in NSCLC patients.. Journal of Clinical Oncology, 2012, 30, 2573-2573.	0.8	9
53	The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. Cancer Immunity, 2012, 12, 6.	3.2	8
54	MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Modern Pathology, 2011, 24, 829-835.	2.9	39

#	ARTICLE	IF	CITATIONS
55	The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. <i>Vaccine</i> , 2011, 29, 3832-3836.	1.7	16
56	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients. <i>PLoS ONE</i> , 2011, 6, e21418.	1.1	42
57	Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. <i>Annals of Hematology</i> , 2011, 90, 89-94.	0.8	15
58	Performance of different data sources in identifying adverse drug events in hospitalized patients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 909-918.	0.8	4
59	Gemcitabine depletes regulatory T cells in human and mice and enhances triggering of vaccine-specific cytotoxic T cells. <i>International Journal of Cancer</i> , 2011, 129, 832-838.	2.3	69
60	Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer. <i>Case Reports in Oncology</i> , 2011, 4, 16-18.	0.3	15
61	Efficient <i>in vivo</i> Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 861-870.	3.2	63
62	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e21366.	1.1	47
63	β -Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens <i>In Vitro</i> and <i>In Vivo</i> . <i>PLoS ONE</i> , 2011, 6, e28217.	1.1	127
64	Abstract 5530: Evidence for immunological pressure and escape from longitudinal analysis of the expression of and immune responses against NY-ESO-1 in a patient with metastatic melanoma. , 2011, , .		0
65	Abstract 5516: Therapeutic vaccination with the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. , 2011, , .		0
66	Abstract 4741: Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1. , 2011, , .		0
67	Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. <i>Swiss Medical Weekly</i> , 2011, 141, w13203.	0.8	8
68	Increased Bone Marrow Activity on F-18-FDG PET/CT in Granulocyte Colony Stimulating Factor Producing Anaplastic Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 103-104.	0.7	17
69	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. <i>Journal of Immunotherapy</i> , 2010, 33, 848-858.	1.2	131
70	Particle size and activation threshold: a new dimension of danger signaling. <i>Blood</i> , 2010, 115, 4533-4541.	0.6	103
71	Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. <i>Annals of Hematology</i> , 2010, 89, 783-787.	0.8	21
72	Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. <i>Pathology International</i> , 2010, 60, 726-734.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2010, 62, 1224-1235.	6.7	65
74	NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. <i>Yeast</i> , 2010, 27, 919-931.	0.8	5
75	Quantitative Computed Tomography Liver Perfusion Imaging Using Dynamic Spiral Scanning With Variable Pitch. <i>Investigative Radiology</i> , 2010, 45, 419-426.	3.5	71
76	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 3562-3570.	3.2	51
77	Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer. <i>Journal of Immunology</i> , 2010, 185, 3095-3102.	0.4	10
78	Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15187-15192.	3.3	21
79	Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. <i>Oncology</i> , 2010, 79, 93-97.	0.9	7
80	Developments in Cancer Immunotherapy. <i>Digestive Diseases</i> , 2010, 28, 51-56.	0.8	10
81	Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – A phase II study. <i>Gynecologic Oncology</i> , 2009, 112, 384-388.	0.6	21
82	Frequent expression of the novel cancer testis antigen MAGE-C2/CTA-10 in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2009, 124, 352-357.	2.3	63
83	Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFN γ . <i>International Journal of Cancer</i> , 2009, 125, 115-123.	2.3	37
84	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 325-338.	2.0	27
85	Rational development of high-affinity T-cell receptor-like antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5784-5788.	3.3	109
86	Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. <i>Cancer Immunity</i> , 2009, 9, 2.	3.2	5
87	Distinct expression patterns of the immunogenic differentiation antigen NY-ESO-1 in normal breast, testis and their malignant counterparts. <i>International Journal of Cancer</i> , 2008, 122, 1585-1591.	2.3	20
88	Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 871-881.	2.0	23
89	Targeted therapeutic approach for an anaplastic thyroid cancer <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2008, 99, 1847-1852.	1.7	18
90	New Derivatives of Vitamin B12 Show Preferential Targeting of Tumors. <i>Cancer Research</i> , 2008, 68, 2904-2911.	0.4	117

#	ARTICLE	IF	CITATIONS
91	Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Journal of Clinical Oncology</i> , 2008, 26, 1435-1442.	0.8	689
92	Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 2526-2531.	0.8	174
93	Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. <i>European Journal of Dermatology</i> , 2008, 18, 566-70.	0.3	25
94	Infarction-Like Electrocardiographic Changes Due to a Myocardial Metastasis From a Primary Lung Cancer. <i>Circulation</i> , 2007, 115, e320-1.	1.6	3
95	Treatment of POEMS syndrome with bevacizumab. <i>Haematologica</i> , 2007, 92, 1438-1439.	1.7	67
96	An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer. <i>Oncology Research and Treatment</i> , 2007, 30, 355-360.	0.8	25
97	NY-BR-1 is a Differentiation Antigen of the Mammary Gland. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 77-83.	0.6	33
98	Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin. <i>Journal of Immunology</i> , 2007, 178, 320-329.	0.4	309
99	NY-ESO-1 protein expression in primary breast carcinoma and metastases correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. <i>International Journal of Cancer</i> , 2007, 120, 2411-2417.	2.3	65
100	The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 2635-2642.	2.3	31
101	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. <i>International Journal of Cancer</i> , 2007, 121, 2042-2048.	2.3	25
102	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1723-1731.	2.0	55
103	Expansion of Umbilical Cord Blood Hematopoietic Stem Cells for Clinical Use.. <i>Blood</i> , 2007, 110, 4049-4049.	0.6	0
104	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. <i>Cancer Immunity</i> , 2007, 7, 16.	3.2	41
105	A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. <i>Journal of Immunology</i> , 2007, 178, 2617-21.	0.4	38
106	NY-ESO-1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	1.9	311
107	Potential use of humanized antibodies in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1065-1074.	1.1	17
108	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 249-258.	2.0	17

#	ARTICLE	IF	CITATIONS
109	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. <i>International Journal of Cancer</i> , 2006, 118, 668-674.	2.3	11
110	Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m ² Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2006, 70, 141-146.	0.9	51
111	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 2745-2751.	3.2	42
112	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14453-14458.	3.3	202
113	Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins. <i>Journal of Immunology</i> , 2006, 177, 2423-2430.	0.4	31
114	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. <i>Journal of Immunology</i> , 2006, 177, 8212-8218.	0.4	24
115	Differentiation of Non-Adherent Hematopoietic Stem Cells from Umbilical Cord Blood Cells into Adherent Hepatocytic Lineage. <i>Blood</i> , 2006, 108, 2578-2578.	0.6	1
116	Cancer immunity hits multiple myeloma. <i>Blood</i> , 2005, 105, 3765-3766.	0.6	1
117	Antibodies and vaccines—hope or illusion?. <i>Breast</i> , 2005, 14, 631-635.	0.9	20
118	Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. <i>International Journal of Cancer</i> , 2005, 117, 800-806.	2.3	20
119	Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 239-239.	1.4	0
120	Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma. <i>Cancer Research</i> , 2005, 65, 3937-3941.	0.4	56
121	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. <i>Breast Cancer Research</i> , 2005, 7, R617-26.	2.2	84
122	Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. <i>Cancer Immunity</i> , 2005, 5, 11.	3.2	39
123	Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 144-147.	2.0	48
124	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. <i>Journal of Immunological Methods</i> , 2003, 278, 57-66.	0.6	46
125	Antigen-specific immunotherapy and cancer vaccines. <i>International Journal of Cancer</i> , 2003, 106, 817-820.	2.3	83
126	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8862-8867.	3.3	179

#	ARTICLE	IF	CITATIONS
127	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. <i>Journal of Immunology</i> , 2003, 170, 1191-1196.	0.4	50
128	Antibody and T-cell responses to the NY-ESO-1 antigen. , 2003, , 191-197.		0
129	Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes. <i>Journal of Immunology</i> , 2002, 168, 2766-2772.	0.4	8
130	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11813-11818.	3.3	83
131	Identification of cancer/testis genes by database mining and mRNA expression analysis. <i>International Journal of Cancer</i> , 2002, 98, 485-492.	2.3	111
132	Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue. <i>International Journal of Cancer</i> , 2002, 97, 64-71.	2.3	16
133	Clinical cancer vaccine trials. <i>Current Opinion in Immunology</i> , 2002, 14, 178-182.	2.4	115
134	Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. <i>Cancer Research</i> , 2002, 62, 4041-7.	0.4	149
135	Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. <i>Cancer Immunity</i> , 2002, 2, 5.	3.2	31
136	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. <i>Cancer Immunity</i> , 2002, 2, 12.	3.2	14
137	Antigen recognition by T cells: a strong sense of structure. <i>Trends in Immunology</i> , 2001, 22, 599-601.	2.9	3
138	Vaccination for Malignant Melanoma: Recent Developments. <i>Oncology</i> , 2001, 60, 1-7.	0.9	65
139	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. <i>Journal of Immunology</i> , 2000, 165, 948-955.	0.4	161
140	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1-Expressing Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 191, 625-630.	4.2	196
141	Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. <i>International Journal of Cancer</i> , 2000, 86, 538-547.	2.3	105
142	Cancer immunotherapy in clinical oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, S46-S51.	1.1	27
143	CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 143-150.	2.7	52
144	Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer. , 1999, 81, 125-133.		32

#	ARTICLE	IF	CITATIONS
145	Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. , 1999, 81, 979-984.		13
146	Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. , 1999, 84, 506-510.		194
147	Antigens recognized by autologous antibody in patients with renal-cell carcinoma. , 1999, 83, 456-464.		146
148	Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker Genes. Human Gene Therapy, 1998, 9, 53-62.	1.4	31
149	A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. Journal of Experimental Medicine, 1998, 187, 1349-1354.	4.2	642
150	Simultaneous Humoral and Cellular Immune Response against Cancer's Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2's binding Peptide Epitopes. Journal of Experimental Medicine, 1998, 187, 265-270.	4.2	668
151	Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer, 1997, 71, 142-147.	2.3	287
152	SSX: A multigene family with several members transcribed in normal testis and human cancer. , 1997, 72, 965-971.		190
153	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162-169.		200
154	Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. , 1996, 66, 470-476.		243
155	Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. , 1996, 67, 54-62.		261
156	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162.		6
157	Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genetics and Cytogenetics, 1995, 80, 138-149.	1.0	35
158	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunology, Immunotherapy, 1994, 39, 93-99.	2.0	42
159	Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-Lymphocyte (CTL) clones. International Journal of Cancer, 1994, 59, 837-842.	2.3	55
160	Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. Hepatology, 1994, 19, 145-154.	3.6	24
161	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunology, Immunotherapy, 1994, 39, 93-99.	2.0	3
162	Lysis of human pancreatic adenocarcinoma cells by autologous hla-class I-restricted cytolytic T-lymphocyte (CTL) clones. International Journal of Cancer, 1993, 54, 636-644.	2.3	46

#	ARTICLE	IF	CITATIONS
163	Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. <i>International Journal of Cancer</i> , 1993, 55, 465-470.	2.3	8
164	Cellular and humoral immune responses against cancer: implications for cancer vaccines. <i>Current Opinion in Immunology</i> , 1991, 3, 659-664.	2.4	22
165	Response to monoclonal antibodies in melanoma: Specific or non-specific?. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1285-1288.	0.9	2
166	Hepatocellular carcinoma after thorotrast exposure: Establishment of a new cell line (Mz-Hep-1). <i>Hepatology</i> , 1985, 5, 1112-1119.	3.6	21
167	Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. <i>Cellular Immunology</i> , 1984, 83, 398-403.	1.4	12